15.57
0.03 (0.16%)
| Previous Close | 15.54 |
| Open | 15.54 |
| Volume | 898,447 |
| Avg. Volume (3M) | 5,561,026 |
| Market Cap | 4,818,718,720 |
| Price / Book | 1.62 |
| 52 Weeks Range | |
| Earnings Date | 19 Mar 2026 |
| Diluted EPS (TTM) | -0.570 |
| Total Debt/Equity (MRQ) | 12.72% |
| Current Ratio (MRQ) | 12.35 |
| Operating Cash Flow (TTM) | -107.72 M |
| Levered Free Cash Flow (TTM) | -91.89 M |
| Return on Assets (TTM) | -22.16% |
| Return on Equity (TTM) | -45.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Erasca, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.38 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.69% |
| % Held by Institutions | 84.38% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Clear Street, 28.49%) | Buy |
| Median | 15.00 (-3.63%) | |
| Low | 11.00 (Piper Sandler, -29.33%) | Buy |
| Average | 15.33 (-1.51%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 11.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Clear Street | 06 Mar 2026 | 20.00 (28.49%) | Buy | 15.57 |
| HC Wainwright & Co. | 26 Jan 2026 | 15.00 (-3.63%) | Buy | 9.61 |
| 13 Jan 2026 | 11.00 (-29.33%) | Buy | 7.51 | |
| Piper Sandler | 16 Jan 2026 | 11.00 (-29.33%) | Buy | 9.62 |
| 07 Jan 2026 | 5.00 (-67.88%) | Buy | 5.17 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Erasca to Present at Upcoming Conferences in February |
| 23 Jan 2026 | Announcement | Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| 21 Jan 2026 | Announcement | Erasca Announces Pricing of Upsized Public Offering of Common Stock |
| 20 Jan 2026 | Announcement | Erasca Announces Proposed Public Offering of $150 Million of Common Stock |
| 14 Jan 2026 | Announcement | Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff |
| 12 Jan 2026 | Announcement | Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones |
| 06 Jan 2026 | Announcement | Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |